ATRA Atara Biotherapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1604464 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY1,404.0%
TTM net income YoY69.1%
TTM EPS YoY82.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-64.7%
Net margin-66.2%
FCF margin-53.5%
EBITDA margin-61.8%
Returns
ROE-8,768.3%
ROA-62.2%
ROIC (approx.)—
Asset turnover0.94x
Leverage & solvency
Liabilities / assets189.2%
Debt / equity—
Current ratio0.48x
Interest coverage-18.08x
Cash quality & payout
Operating cash flow / net income0.80x
Accruals ratio-12.2%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $120.77M | $128.94M | $8.57M | $63.57M | — |
| R&D expense | $37.45M | $151.48M | $224.78M | $272.53M | $282.00M |
| SG&A expense | $26.25M | $39.89M | $50.91M | $71.55M | $78.80M |
| Operating income | $35.86M | -$83.44M | -$276.01M | -$280.51M | -$340.46M |
| Interest expense | $3.79M | $4.62M | $5.29M | $373,000 | — |
| Pretax income | $32.72M | -$85.42M | -$276.11M | -$228.29M | -$340.10M |
| Income tax | $31,000 | -$12,000 | $15,000 | $12,000 | $46,000 |
| Net income | $32.69M | -$85.40M | -$276.13M | -$228.30M | -$340.14M |
| EBITDA | $37.98M | -$78.39M | -$271.18M | -$274.86M | -$331.12M |
| EPS (basic) | 2.61 | -11.41 | -65.19 | -2.24 | -3.63 |
| EPS (diluted) | 2.57 | -11.41 | -65.19 | -2.24 | -3.63 |
| Weighted avg. shares (diluted) | 12.72M | 7.49M | 4.24M | 101.99M | 93.67M |
| Balance sheet | |||||
| Cash & equivalents | $8.48M | $25.18M | $25.99M | $93.09M | $107.48M |
| Short-term investments | $0 | $17.47M | $25.88M | $149.88M | $264.98M |
| Receivables | $1.25M | $1.48M | $34.11M | $40.22M | $986,000 |
| Inventory | $0 | $10.65M | $9.71M | $1.59M | $0 |
| Current assets | $12.21M | $64.89M | $101.87M | $295.08M | $384.62M |
| PP&E, net | $73,000 | $1.29M | $3.86M | $6.30M | $53.78M |
| Total assets | $20.23M | $109.10M | $165.50M | $376.42M | $468.13M |
| Current liabilities | $14.92M | $134.57M | $142.23M | $78.92M | $105.79M |
| Total liabilities | $58.74M | $206.38M | $264.74M | $249.78M | $188.51M |
| Shareholders' equity | -$38.50M | -$97.28M | $99.23M | $126.64M | $279.61M |
| Shares outstanding | 7.32M | 5.86M | 4.26M | 95.93M | 91.67M |
| Cash flow statement | |||||
| Operating cash flow | -$50.94M | -$68.72M | -$192.98M | -$270.43M | -$220.52M |
| Capital expenditure | $0 | $246,000 | $1.22M | $4.19M | $10.58M |
| Free cash flow | -$50.94M | -$68.96M | -$194.20M | -$274.62M | -$231.10M |
| Investing cash flow | $18.15M | $8.62M | $123.87M | $202.96M | $22.26M |
| Financing cash flow | $16.10M | $59.28M | $2.01M | $53.08M | $103.94M |
| Depreciation & amortization | $2.12M | $5.05M | $4.83M | $5.65M | $9.35M |
| Stock-based compensation | $9.75M | $27.00M | $45.39M | $53.84M | $53.87M |
Free plan shows the latest 5 periods; Pro shows all 14 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.